A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: An NRG oncology/gynecologic oncology group study

International Journal of Gynecological Cancer

Volumn 25, Issue 3, 2015, Pages 484-492

  Kunos, Charles ^a   Deng, Wei ^b   Dawson, Dawn ^c   Lea, Jayanthi S ^d   Zanotti, Kristine M ^e   Gray, Heidi J ^f   Bender, David P ^g   Guaglianone, Perry P ^h   Carter, Jori S ⁱ   Moore, Kathleen N ^j  

^a SUMMA HEALTH SYSTEM   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h Decatur Memorial Hospital   (United States)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^j UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

Cervical cancer; Poly (ADP ribose) polymerase; Topotecan; Veliparib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FILGRASTIM; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PEGFILGRASTIM; RIBONUCLEOTIDE REDUCTASE; TOPOTECAN; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CELL CYCLE PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PARP2 PROTEIN, HUMAN; RECOMBINANT PROTEIN; RRM2B PROTEIN, HUMAN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EAR DISEASE; ENDOCRINE DISEASE; ENDOMETRIUM CARCINOMA; EVALUATION STUDY; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; INJURY; INNER EAR DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; MENTAL DISEASE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEOPLASM; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NUTRITIONAL DISORDER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; VASCULAR DISEASE; ANEMIA; CARCINOMA; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CARCINOMA; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINANT PROTEINS; RIBONUCLEOTIDE REDUCTASES; THROMBOCYTOPENIA; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 84924426159     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000380     Document Type: Article

References (35)

1. Chambon P, Weill J, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesising nuclear enzyme. Biochem Biophys Res Commun. 1963;11:39-43.
2. Dantzer F, de la Rubia G, Menissier-de Murcia J, et al. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry. 2000;39:7559-7569.
3. Schreiber V, Ame J, Dollie P, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision repair in association with PARP-1 and XRCC1. J Biol Chem. 2002;277:23028-23036.
4. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39:8-24.
5. Shunkwiler L, Ferris G, Kunos C. Inhibition of poly(ADP-ribose) polymerase enhances radiochemosensitivity in cancers proficient in DNA double-strand break repair. Int J Mol Sci. 2013;14:3773-3785.
6. Chalmers AJ. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller, and therapeutic target. Clin Oncol. 2004;16:29-39.
7. Loser DA, Shibata A, Shibata AK, et al. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther. 2010;9:1775-1787.
8. Fernet M, Ponette V, Deniaud-Alexandre E, et al. Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation. Int J Radiat Oncol Biol Phys. 2000;76:1621-1629.
9. Ame J, Rolli V, Schreiber V, et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem. 1999;274:17860-17868.
10. Ame J, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004;26:882-893.
11. Delaney C, Wang L, Kyle S, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000;6:2860-2867.
12. Donawho C, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13:2728-2737.
13. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly(ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27:2705-2711.
14. Patel AG, Flatten KS, Schneider PA, et al. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem. 2012;287:4198-4210.
15. D'Onofrio G, Tramontano F, Dorio AS, et al. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. Biochem Pharmacol. 2011;81:194-202.
16. Fukushima M, Kuzuya K, Ota K, et al. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett. 1981;14:227-236.
17. Gonen M. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in phase I trials. Contemp Clin Trials. 2005;26:131-140.
18. Chen TT, Ng TH. Optimal flexible designs in phase II clinical trials. Stat Med. 1998;17:2301-2312.
19. Kunos C, Winter K, Dicker A, et al. Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int J Gynecol Cancer. 2013;23:615-621.
20. Kunos C, Chiu S, Pink J, et al. Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiation Res. 2009;172:666-676.
21. Kunos C, Radivoyevitch T, Pink J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res . 2010;174:574-581.
22. Kunos C, Radivoyevitch T, Waggoner S, et al. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol. 2013;130:75-80.
23. Kunos C, Waggoner S, Von Gruenigen V, et al. Phase I trial of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in combination with pelvic radiation therapy and weekly cisplatin chemotherapy for locally advanced cervical cancer. Clin Cancer Res. 2010;16:1298-1306.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Snedecor G, Cochran W. Statistical Methods. Ames, IA: Iowa State University Press; 1989.
26. Good P. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. New York: Springer; 2000.
27. Klein J, Moeschberger M. Survival Analysis Techniques for Censored and Truncated Data. New York: Springer; 2003.
28. Cox D. Regression models and life tables (with discussion). J R Stat Soc. 1972;34:187-220.
29. Staker B, Hjerrild K, Feese M, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A. 2002;99:15387-15392.
30. Hakansson P, Hofer A, Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem. 2006;281:7834-7841.
31. Xue L, Zhou B, Liu X, et al. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res. 2003;63:980-986.
32. Zamboni WC, D'Argenio DZ, Stewart CF, et al. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res . 2001;7:2301-2308.
33. Leger F, Loos WJ, Bugat R, et al. Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther. 2004;76:567-578.
34. Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol. 2000;78:97-105.
35. Farley JH, Hickey KW, Carlson JW, et al. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer. 2003;97:2196-2202.